168 related articles for article (PubMed ID: 37305018)
21. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
22. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF; Freeman JL; Orihuela E; Goodwin JS
J Clin Oncol; 2007 Dec; 25(34):5359-65. PubMed ID: 18048816
[TBL] [Abstract][Full Text] [Related]
24. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.
Gillessen S; Templeton A; Marra G; Kuo YF; Valtorta E; Shahinian VB
J Natl Cancer Inst; 2010 Dec; 102(23):1760-70. PubMed ID: 21068432
[TBL] [Abstract][Full Text] [Related]
25. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
[TBL] [Abstract][Full Text] [Related]
26. The evolving role of immune cells in prostate cancer.
Wang C; Zhang Y; Gao WQ
Cancer Lett; 2022 Jan; 525():9-21. PubMed ID: 34715253
[TBL] [Abstract][Full Text] [Related]
27. Use of androgen deprivation therapy in prostate cancer: indications and prevalence.
Connolly RM; Carducci MA; Antonarakis ES
Asian J Androl; 2012 Mar; 14(2):177-86. PubMed ID: 22231299
[TBL] [Abstract][Full Text] [Related]
28. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor: past, present and future.
Schmidt LJ; Tindall DJ
Curr Drug Targets; 2013 Apr; 14(4):401-7. PubMed ID: 23565753
[TBL] [Abstract][Full Text] [Related]
30. Androgens and prostate cancer; pathogenesis and deprivation therapy.
Grossmann M; Cheung AS; Zajac JD
Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
[TBL] [Abstract][Full Text] [Related]
31. Cadherin switching in human prostate cancer progression.
Tomita K; van Bokhoven A; van Leenders GJ; Ruijter ET; Jansen CF; Bussemakers MJ; Schalken JA
Cancer Res; 2000 Jul; 60(13):3650-4. PubMed ID: 10910081
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
33. Androgen deprivation therapy for prostate cancer.
Singer EA; Golijanin DJ; Miyamoto H; Messing EM
Expert Opin Pharmacother; 2008 Feb; 9(2):211-28. PubMed ID: 18201145
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
35. The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression.
Olson A; Le V; Aldahl J; Yu EJ; Hooker E; He Y; Lee DH; Kim WK; Cardiff RD; Geradts J; Sun Z
PLoS Genet; 2019 Oct; 15(10):e1008451. PubMed ID: 31658259
[TBL] [Abstract][Full Text] [Related]
36. Self-care Experiences of Advanced Prostate Cancer Survivors Who Underwent Androgen Deprivation Therapy.
Chien CH; Huang XY
Cancer Nurs; 2022 May-Jun 01; 45(3):190-200. PubMed ID: 33654010
[TBL] [Abstract][Full Text] [Related]
37. Profiling Prostate Cancer Therapeutic Resistance.
Wade CA; Kyprianou N
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
[TBL] [Abstract][Full Text] [Related]
38. Activation of estrogen receptor beta (ERβ) regulates the expression of N-cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells.
Silva RS; Lombardi APG; de Souza DS; Vicente CM; Porto CS
Int J Biochem Cell Biol; 2018 Mar; 96():40-50. PubMed ID: 29341930
[TBL] [Abstract][Full Text] [Related]
39. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.
Zapatero A; Guerrero A; Maldonado X; Álvarez A; San-Segundo CG; Rodríguez MÁC; Solé JM; Olivé AP; Casas F; Boladeras A; de Vidales CM; de la Torre MLV; Vara S; Sanz JL; Calvo FA
Lancet Oncol; 2022 May; 23(5):671-681. PubMed ID: 35427469
[TBL] [Abstract][Full Text] [Related]
40. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
